About The Doctor

Dr. Hossein Borghaei

Medical Oncologist , Chief, Thoracic Medical Oncology

Dr. Hossein Borghaei, M.D., has adopted a patient-centric approach when it comes to caring for those diagnosed with cancer. This means that over the course of treatment, he looks at the unique type of cancerous cells that the person has been diagnosed with. In addition, he pays close attention to their social, personal and family needs. Working at the Fox Chase Cancer Center, Dr. Borghaei has used a variety of drugs in the attempt to treat a variety of different cancers like lung cancers, lymphoma, chest cancers and mesothelioma. Mesothelioma is a rare and aggressive type that develops as a person has been exposed to asbestos fibers.

Get In Touch


Dr. Hossein Borghaei earned his medical degree from Philadelphia College of Osteopathic Medicine. He completed his internal medicine residency at the Graduate Hospital in Philadelphia and his hematology/oncology fellowship at the Fox Chase Cancer Center in Philadelphia, where he currently practices as a medical oncologist.

Dr. Borghaei’s special areas of interest include lung cancer, targeted therapy, monoclonal antibody therapy, immunotherapy, and cancer vaccines. With regard to lung cancer, he is especially passionate about prevention and early detection of the disease.

A Message of Hope

Dr. Hossein Borghaei works to improve his patients’ immune response to cancer.

Principal Investigator

Dr. Borghaei’s laboratory works to develop new cancer treatments within the field of immunotherapy. These therapies include monoclonal antibody drugs, among drugs, and cancer vaccines to improve his patients’ immune response to cancer.

Lifelong Battle

Dr. Borghaei recognizes that relapses with cancer are common, especially with asbestos-related cancers like mesothelioma and lung cancer. When these cancers are said to have gone into remission, it does not mean that the cancer is gone for good. Sometimes it returns, complicating treatment.

The biggest problem is how after a while, cancerous cells can adapt and become resistant to some of the chemotherapeutic drugs, another reason why Dr. Borghaei works to connect his patients with novel treatments like immunotherapy to help provide them with the best care.

Article Sources